FSL-1 TFA
Based on 4 publication(s) in Google Scholar
FSL-1 TFA, a bacterial-derived toll-like receptor 2/6 (TLR2/6) agonist, enhances resistance to experimental HSV-2 infection. FSL-1 TFA induces MMP-9 production through TLR2 and NF-κB/AP-1 signaling pathways in monocytic THP-1 cells.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.81%
- Fòrmula: C84H140N14O18S.xC2HF3O2
- Peso molecular:1666.16 (free acid)
-
Almacenamiento:
-80°C
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) FSL-1 TFA
MoreVer todos los productos específicos de isoformas Antibiotic
More
Actividad biológica
|
TLR2 |
HSV-2 |
TLR6 |
MMP-9 |
FSL-1 TFA significantly reduces HSV-2 replication in human vaginal epithelial cells (EC)[1].
FSL-1 TFA induces significant resistance to experimental genital HSV-2 infection through elaboration of a specific cytokine response profile[1].
FSL-1 TFA (50 ng/mL, 24 hours) induces MMP-9 expression at both mRNA and protein levels in human monocytic THP-1 cells[2].
FSL-1 TFA activates the MAP kinase/NF-κB signaling pathway[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:V11I, V12I or V19I immortalized human vaginal EC
-
Concentration:6 μg or 0.1 μg
-
Incubation Time:Added at 24, 6 or just prior to HSV-2 inoculation (104pfu/well)
-
Result:The 6 μg does produced significant reductions when delivered at 24 or 6 h prior to HSV-2 inoculation. The 0.1 μg dose produced reduced HSV-2 replication at 24 or 6 h prior to viral challenge.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female Swiss-Webster mice (weighing 20-25 g)[1]
-
Dosage:2 or 6 μg
-
Administration:Delivered vaginally using a positive displacement pipet, prior to or following viral challenge as specified for each experiment.
-
Result:The 2 μg does delivered 6 h prior to HSV-2 challenge increased the ID50 (260 pfu) and LD50 (660 pfu) by 10-fold compared to DPBS vehicle control.
The single 6 μg dose produced significantly improved outcomes compared to DPBS vehicle application.
Chemical Information
-
Appearance Solid
-
Peso molecular 1666.16 (free acid)
-
Fòrmula C84H140N14O18S.xC2HF3O2
-
Color White to off-white
-
Sequence Shortening
S-(2, 3-Bispalmitoyloxypropyl)-CGDPKHPKSF
-
Envío
Shipping with dry ice.
-
Almacenamiento
-80°C
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
Calhm6 Governs Macrophage Polarization Through Chp1-Camk4-Creb1 Axis and Ectosomal Delivery in Inflammatory Responses. [Abstract]2025 Sep 26:e02395. PMID: 40999918 -
Food Res Int
Walnut-derived peptides ameliorate d-galactose-induced memory impairments in a mouse model via inhibition of MMP-9-mediated blood-brain barrier disruption. [Abstract]2022 Dec;162(Pt A):112029. PMID: 36461249 -
J Ethnopharmacol
Cornus officinalis var. koreana Kitam extracts alleviate cadmium-induced renal fibrosis by targeting matrix metallopeptidase 9. [Abstract]2024 May 10:325:117824. PMID: 38278375 -
Int J Med Sci
SJMHE1 protects against excessive iodine-induced pyroptosis in human thyroid follicular epithelial cells through a toll-like receptor 2-dependent pathway. [Abstract]2022 Mar 21;19(4):631-639. PMID: 35582426
Solvente y solubilidad
H2O : 50 mg/mL (Need ultrasonic)
DMSO : 25 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Pureza y Documentación
-
Ficha de datos (270 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. William A Rose 2nd, et al. FSL-1, a bacterial-derived toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection. Virol J. 2009 Nov 10;6:195. [Content Brief]
[2]. Cathryn J Kurkjian,et al. The Toll-Like Receptor 2/6 Agonist, FSL-1 Lipopeptide, Therapeutically Mitigates Acute Radiation Syndrome. Sci Rep. 2017 Dec 11;7(1):17355. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz